Patents by Inventor Heng-Hsiung Wu

Heng-Hsiung Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTAGONIST OF INTERLEUKIN-17B RECEPTOR (IL-17RB) AND USE THEREOF
    Publication number: 20240124528
    Abstract: The present invention relates to an antagonist of interleukin-17B receptor (IL-17RB) which features interruption of the interaction of IL-17RB and MLK4. The present invention also relates to use of such antagonist for treatment of diseases or disorders associated with IL-17RB activation. Further disclosed is a phosphorylated IL-17RB as a biomarker for predicting prognosis and/or monitoring progression of cancer.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 18, 2024
    Applicant: Academia Sinica
    Inventors: Wen-Hwa LEE, Heng-Hsiung WU, Chun-Mei HU, Chun-Kai HUANG
  • Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy
    Patent number: 10793628
    Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 6, 2020
    Assignee: Academia Sinica
    Inventors: Wen-Hwa Lee, Jin-Yuh Shew, Che Ma, Chia-Lin Chen, Wen-Hsin Lee, Chun-Kai Huang, Heng-Hsiung Wu
  • ANTAGONISTS FOR INTERLEUKIN-17 RECEPTOR B (IL-17RB) AND ITS LIGAND IL-17B FOR CANCER THERAPY
    Publication number: 20180201672
    Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.
    Type: Application
    Filed: June 30, 2015
    Publication date: July 19, 2018
    Applicant: Academia Sinica
    Inventors: Wen-Hwa Lee, Jin-Yuh Shew, Che Ma, Chia-Lin Chen, Wen-Hsin Lee, Chun-Kai Huang, Heng-Hsiung Wu